Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

3 Apr 2019

New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.

New research at the University of Warwick is underway to prove how well curcumin and pomegranates can hack autophagy to prevent Alzheimer’s disease.

Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

The hope is that the studies will show that this naturally-occurring compounds found especially in turmeric can - when combined with intermittent fasting - prevent the build-up of damaging protein fragments that form between nerve cells in the brain and cause neurological problems.

It’s thought that these fragments may be produced as part of the brain’s self-defence process and that their presence is a symptom of the disease. In a healthy brain, these fragments are broken down and eliminated, but problems occur if they begin to accumulate and form the hard, insoluble amyloid plaques known to be one of the major symptoms of Alzheimer's disease.

Previous related research at the Chinese University of Hong Kong in 2008 found that Biocurcumax, a patented extract available as a food supplement, helped prevent further build-up of these amyloid plaques and subsequently was approved by the FDA for investigational Therapy.

The importance of curcumin seems to hinge on its ability to kick-start the cleansing process that otherwise can take up to eighteen hours of fasting for the body to begin by itself. The studies to date have shown that when curcumin is highly ‘bio-available’ - present in the bloodstream in potent amounts for a long-enough period of time – it can help autophagy start much sooner. Biocurcumax is a food supplement designed to allow active curcumin to be retained in the body for more than 8 hours.

Suphil Philipose, of BioTurm, the UK distributor of Biocurcumax says: "Research has already shown that highly bio-available curcumin, when combined with the essential oil of turmeric, can stop the progressive build-up of neurologically-damaging substances. This new research opens up a new world of hope to millions of people.”

Research conducted with the University of Rome in 2015 showed Biocurcumax was able to reverse the dysfunction that sometimes occurs in autophagy, the self-cleansing process.

New studies at the University of Warwick will now seek to show the actual extent to which curcumin and pomegranates can induce autophagy and remove the damaged cells. Should these prove successful, they will progress to a human clinical trial to demonstrate the efficacy of the solution.

Crucially curcumin is thought to also have a positive effect on apoptosis - the normal, controlled death of billions of cells in the adult body every day. Curcumin also restores and maintains a healthy mitochondria, the 'battery unit' of every cell.

Philipose adds: “Nature provides us with curcumin and pomegranates that can be used as hacks to induce and kick start the self-cleansing mechanism in the body. Adjunct to a fasting diet, we may have a pathway for preventing the disease.”


Read More

Related news

Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offer an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
Catalent expands OptiMelt hot melt extrusion capabilities

Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Read more 
'Drugs from bugs' joint venture

'Drugs from bugs' joint venture

4 Apr 2019

Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.

Read more 
MedPharm's appointment with Destiny

MedPharm's appointment with Destiny

28 Mar 2019

Global contract provider to develop new XF-platform drug formulations for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.

Read more 
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
Envigo launches PATHWAY to enable FIH clinical trials

Envigo launches PATHWAY to enable FIH clinical trials

11 Mar 2019

PATHWAY manages the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers.

Read more 
Biogen acquisition boosts its ophthalmology pipeline

Biogen acquisition boosts its ophthalmology pipeline

4 Mar 2019

Nightstar Therapeutics has two potentially first-in-class mid- to late-stage clinical assets as well as preclinical programs.

Read more 
Uniqsis expands LED photoreactor range

Uniqsis expands LED photoreactor range

3 Mar 2019

The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.

Read more 
Crowdfund and discover promising therapeutics via Molecule

Crowdfund and discover promising therapeutics via Molecule

21 Feb 2019

Connecting scientists, patients, and industry to advance drug development in a collaborative open market.

Read more